On March 5, 2018 Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , reported that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT (Press release, Endocyte, MAR 5, 2018, http://investor.endocyte.com/news-releases/news-release-details/endocyte-present-cowen-and-company-38th-annual-health-care [SID1234524390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Company’s presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

ArQule has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, ArQule, 2018, MAR 5, 2018, View Source [SID1234524375]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 5, 2018 SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, reported that the Company will present at the Cowen and Company 38th Annual Health Care Conference (Press release, SpringWorks Therapeutics, MAR 5, 2018, View Source [SID1234538853]). SpringWorks Therapeutics’ President and Founder Lara S. Sullivan, M.D., is scheduled to present at 9:00 a.m. ET on Monday, March 12, 2018 at the Boston Marriott Copley Place.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 5, 2018 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, reported that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will present at the Cowen & Company 38th Annual Health Care Conference on Monday, March 12th, 2018, at 2:50 p.m. Eastern Time (ET) (Press release, Rocket Pharmaceuticals, MAR 5, 2018, View Source [SID1234524360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

On March 5, 2018 pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker, President and Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 30th Annual ROTH Conference on Monday, March 12, 2018, at 5:00 p.m. ET (Press release, pSivida, MAR 5, 2018, View Source [SID1234524369]). The conference will be held at the Ritz Carlton, Laguna Nigel in Orange County, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio and/or webcast and subsequent archived replay of pSivida’s presentation may be accessed via the Investors section of the Company’s website under "Resources – Events & Presentations" at www.psivida.com. The replay will be available for 90 days after the event.